(Video) Analyst breaks down Hims' 2030 $6.5 billion revenue model + Who is actually selling off?

This episode of the Hims house podcast (recorded in mid-to-late June) features Ryan McDonald, an analyst and chief analyst at Needham. He focuses on analyzing HIMS and its related businesses, with in-depth discussions particularly around peptides, GLP-1 drugs, and other relevant fields. Ryan holds a Buy rating on HIMS with a $35 target price. The content covers FDA regulatory dynamics, market size, industry competition, core business assessments, and future outlook.$Hims & Hers Health(HIMS.US) $Defiance Daily Target 2X Long HIMS ETF(HIMZ.US)